Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00915590 · ClinicalTrials.gov registry record · Phase 1
Topical IL-1-Ra for Treatment of Corneal Neovascularization
A Phase 1 study, sponsored by Reza Dana, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00915590 is a Phase 1 study that was terminated before completion, run by Reza Dana, MD. The registered enrollment target is 10 participants.
The verdict
NCT00915590, a Phase 1 study, was terminated before completion, sponsored by Reza Dana, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.
Interventions
- DRUG Placebo
- DRUG IL-1Ra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00915590
The ClinicalTrials.gov registry entry for NCT00915590 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reza Dana, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00915590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00915590 about?
NCT00915590 is a clinical study titled "Topical IL-1-Ra for Treatment of Corneal Neovascularization". The purpose of this study is to determine the effectiveness and safety of Interleukin-1-Receptor Antagonist eye drops for the treatment of corneal blood vessels.
What is the current status of trial NCT00915590?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2009-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00915590?
The interventions under investigation include: Placebo (DRUG), IL-1Ra (DRUG).
Who is sponsoring clinical trial NCT00915590?
This trial is sponsored by Reza Dana, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.